TML-ONI-21

TML-ONI-21 is a preclinical-stage drug candidate being developed by Themis Medicare. It is categorized as a new dosage form of an immunomodulatory agent, suggesting it utilizes a novel drug delivery system or formulation to enhance the therapeutic profile of an existing or proprietary active ingredient. As of early 2024, the candidate is in the preclinical phase of development, with its specific molecular targets and chemical composition not publicly disclosed. The project is part of Themis Medicare's innovation pipeline, which focuses on developing novel drug delivery systems (NDDS) and new dosage forms across various therapeutic areas including analgesics and anti-malarials.